15th International Conference on Orthopedics, Arthroplasty and Rheumatology
Hospital Santa Creu i Sant Pau, Barcelona
Title: Ustekinumab and TNF Inhibitor Treatment in Spanish Patients with Psoriatic Arthritis: 6-month Follow-up from the Real-world Observational Study PsABio
PsABio (ClinicalTrials: NCT02627768) is a prospective, observational, real-world cohort study collecting data on patients with a confirmed diagnosis of PsA starting either ustekinumab (UST) or a new TNF inhibitor (TNFi) in 8 European countries. The purpose of the study PsABio is to evaluate the efficacy, tolerability and persistence of ustekinumab and TNFis for adult patients with PsA according to CASPAR criteria commencing first-, second- or third- line bDMARDs in real-world routine clinical management.
This interim analysis presents 6-month follow-up data on joint-related outcomes in the Spanish cohort.